疏水性小分子无可逆转的组织转胺酶抑制剂的结构-活性关系
Daniel A Wallace1, Sarah Tribe1, Pauline Navals1
1Department of Chemistry and Biomolecular Sciences, University of Ottawa Ottawa ON N6H 1N5 Canada jkeillor@uottawa.ca.
RSC medicinal chemistry
|November 24, 2025
概括
研究人员优化了小分子抑制剂的组织转谷氨酶 (TG2),一种与疾病相关的蛋白质. 该研究确定了甲衍生物作为体内应用最有前途的候选物,因为它具有强大的抑制和有利的特性.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
背景情况:
- 组织转谷氨酶 (TG2) 是一种多功能酶和G蛋白,与各种疾病有关.
- 小分子TG2抑制剂作为潜在的治疗和研究工具具有价值.
- 之前对TG2抑制剂EB-2-16的优化集中在它的弹头,和桥上.
研究的目的:
- 为了研究TG2抑制剂中悬挂式疏水组的结构-活性关系.
- 识别具有提高功效,膜透性和代谢稳定性的新型TG2抑制剂.
主要方法:
- 合成和评估各种环基,基,二基和亚达曼基衍生物作为TG2抑制剂.
- 确定动力参数 (k_inact,K_I) 和抑制效率 (k_inact/K_I).
- 评估脂质膜透性 (P_e) 和人类肝细胞稳定性 (CL_int).
主要成果:
- 与其他疏水性群体相比,阿达曼基部分表现出更高的亲和力.
- 替代的阿达曼衍生物表现出增强的抑制效率,其中一些超过10^6 M^-1 min^-1.
- 甲胺基抑制剂25b显示出最佳的整体特征,包括高强度 (k_inact/K_I = 941 × 10^3 M^-1 min^-1),良好的膜透性 (P_e = 1.41 × 10^-6 cm s^-1),以及可接受的肝细胞稳定性 (CL_int = 6.91 μL min^-1/10^6 细胞).
结论:
- 疏水性群组的修改显著影响TG2抑制剂的有效性和特性.
- 甲胺基抑制剂25b是进一步开发和体内应用的有希望的候选者,因为它具有平衡的抑制功效和药理动力学特性.
相关概念视频
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
890
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
890
01:30Enzyme Inhibition
91.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.3K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
01:16TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K